Summarized by Masters of Longevity from BioSpace - Funding.
An NIH Phase II small-business grant will support an AI model that integrates metabolomics datasets within Sinopia’s LEADS drug-discovery platform.
Key Takeaways
- The $2.5 million grant funds model development and validation using diverse datasets.
- The broader platform has produced SB-0110, a preclinical Parkinson’s disease candidate.
- The award supports discovery infrastructure; it does not establish clinical efficacy.
